rosiglitazone has been researched along with bucladesine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Berthiaume, M; Deshaies, Y; Festuccia, WT; Gélinas, Y; Laplante, M | 1 |
2 other study(ies) available for rosiglitazone and bucladesine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
PPARgamma agonism increases rat adipose tissue lipolysis, expression of glyceride lipases, and the response of lipolysis to hormonal control.
Topics: Adipose Tissue; Animals; Bucladesine; Energy Intake; Fatty Acid-Binding Proteins; Fatty Acids, Nonesterified; Lipase; Lipolysis; Male; PPAR gamma; Rats; Rats, Sprague-Dawley; RNA; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Weight Gain | 2006 |